Hims & Hers Health Reports Q2 Earnings, Beating Top And Bottom Lines, Raises Guidance
Portfolio Pulse from Ryan Gustafson
Hims & Hers Health, Inc. (NYSE:HIMS) reported Q2 earnings, beating top and bottom lines, and raised its full year 2023 revenue guidance. The company reported quarterly losses of three cents per share, beating the analyst consensus estimate of losses of six cents. Quarterly sales were $207.91 million, beating the analyst consensus estimate of $204.62 million. Subscribers grew to 1.3 million, up 74% YoY. Full year 2023 revenue guidance was raised to between $830 million and $850 million. Credit Suisse analyst Jonathan Yong reiterated Hims & Hers Health with an Outperform and maintained the $14 price target.
August 08, 2023 | 7:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Hims & Hers Health beat Q2 earnings estimates and raised its 2023 revenue guidance. Despite the positive news, the stock traded lower, possibly due to profit-taking after the earnings release.
Hims & Hers Health reported better-than-expected Q2 results and raised its 2023 revenue guidance, which is generally positive news. However, the stock traded lower, which could be due to investors taking profits after the earnings release. The maintained price target by Credit Suisse indicates that analysts still see potential in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100